XORTX Therapeutics Inc. (XRTX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
XORTX Therapeutics Inc. (XRTX) trades at $2.02. XORTX Therapeutics Inc. is a bio-pharmaceutical company focused on developing and commercializing therapies for progressive kidney diseases, diabetes, and related complications. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for XRTX: XRTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates XRTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on XRTX.
How is this calculated? →XORTX Therapeutics Inc. (XRTX) Healthcare & Pipeline Overview
XORTX Therapeutics Inc. is a clinical-stage biopharmaceutical company focusing on kidney disease and related metabolic disorders. Their pipeline includes treatments for autosomal dominant polycystic kidney disease (ADPKD), COVID-19-induced acute kidney injury, and diabetic nephropathy, positioning them in a high-need segment of the healthcare sector.
What Is the Investment Thesis for XRTX?
XORTX Therapeutics presents a notable research candidate due to its focus on addressing significant unmet needs in kidney disease and related metabolic disorders. The late-stage clinical program, XRx-008, targeting ADPKD, offers substantial potential given the limited treatment options currently available. Positive clinical trial results for XRx-008 could serve as a major catalyst, driving significant value appreciation. Furthermore, the development of XRx-101 for COVID-19-related AKI and XRx-221 for diabetic nephropathy diversifies the pipeline and mitigates risk. However, the company's small size and limited resources pose challenges, and clinical trial outcomes are inherently uncertain. With a market cap of $0.00B and a P/E ratio of -0.85, XORTX is a high-risk, high-reward investment.
Based on FMP financials and quantitative analysis
XRTX Key Highlights
XORTX Therapeutics is focused on developing therapies for progressive kidney diseases, including autosomal dominant polycystic kidney disease (ADPKD).
- The company's lead product candidate, XRx-008, is in late-stage clinical development for ADPKD.
- XORTX is developing XRx-101 as a uric acid-lowering agent to treat acute kidney injury associated with COVID-19.
- XRx-221 is a xanthine oxidase inhibitor candidate for the treatment of diabetic nephropathy.
- XORTX has a partnership with the Icahn School of Medicine to study acute kidney injury and hyperuricemia in COVID-19 patients.
Who Are XRTX's Competitors?
XRTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DRMA Dermata Therapeutics, Inc. | $1.38 | -6.12% | — | |
| GTBP GT Biopharma, Inc. | $0.28 | -1.71% | $8.90M | — |
| LEXX Lexaria Bioscience Corp. | $11.51 | -0.09% | $19.0M | 66 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XRTX's Key Strengths?
Focus on unmet needs in kidney disease.
- Late-stage clinical program for ADPKD.
- Potential therapies for COVID-19-related AKI and diabetic nephropathy.
- Partnership with the Icahn School of Medicine.
What Are XRTX's Weaknesses?
Small company with limited resources.
- Dependence on clinical trial outcomes.
- Limited commercialization experience.
- High cash burn rate.
What Could Drive XRTX Stock Higher?
Clinical trial results for XRx-008 in ADPKD patients.
- Regulatory submissions for XRx-008.
- Progress in the development of XRx-101 for COVID-19-related AKI.
- Advancement of XRx-221 for diabetic nephropathy.
- Potential for new strategic partnerships and collaborations.
What Are the Key Risks for XRTX?
Financial-distress signal — its Altman Z-Score of -6.98 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for XRx-008 or other pipeline candidates.
- Regulatory delays or rejections.
- Competition from larger pharmaceutical companies.
- Dependence on securing additional funding.
- Patent expirations and intellectual property challenges.
What Are the Growth Opportunities for XRTX?
- XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The market for ADPKD treatments is expected to grow significantly, driven by the lack of effective therapies and the increasing prevalence of the disease. XORTX's XRx-008, a late clinical-stage program, has the potential to capture a significant share of this market if it demonstrates positive clinical trial results. The timeline for commercialization depends on successful completion of clinical trials and regulatory approval, potentially within the next 3-5 years.
- XRx-101 for COVID-19-Related Acute Kidney Injury (AKI): The COVID-19 pandemic has highlighted the importance of addressing AKI, a common complication of severe infections. XORTX's XRx-101, a uric acid-lowering agent, could play a crucial role in mitigating AKI and improving outcomes for COVID-19 patients. The market opportunity is substantial, given the ongoing pandemic and the potential for future viral outbreaks. Clinical trials and regulatory approval will determine the timeline for commercialization.
- XRx-221 for Diabetic Nephropathy: Diabetic nephropathy is a leading cause of kidney failure, affecting millions of people worldwide. XORTX's XRx-221, a xanthine oxidase inhibitor, has the potential to address this unmet need by slowing the progression of diabetic nephropathy. The market for diabetic nephropathy treatments is large and growing, driven by the increasing prevalence of diabetes. Clinical development and regulatory approval will determine the timeline for commercialization.
- Strategic Partnerships and Collaborations: XORTX can expand its reach and accelerate its development programs through strategic partnerships and collaborations with other companies and research institutions. The company's existing partnership with the Icahn School of Medicine demonstrates its ability to forge valuable collaborations. Future partnerships could provide access to new technologies, funding, and expertise, enhancing XORTX's competitive position.
- Expansion into New Therapeutic Areas: XORTX can leverage its expertise in kidney disease and related metabolic disorders to expand into new therapeutic areas. This could involve developing therapies for other types of kidney disease, such as chronic kidney disease (CKD), or for related conditions, such as diabetes and metabolic syndrome. By diversifying its pipeline, XORTX can reduce its reliance on individual product candidates and increase its overall growth potential.
What Are XRTX's Competitive Advantages?
- Proprietary drug candidates.
- Intellectual property protection.
- Clinical trial data.
- Partnerships with leading research institutions.
What Does XRTX Do?
XORTX Therapeutics Inc., founded to address unmet needs in progressive kidney diseases and related metabolic disorders, is a biopharmaceutical company based in Vancouver, Canada. The company is dedicated to the development and commercialization of innovative therapies targeting conditions such as autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy, and acute kidney injury (AKI) associated with viral infections like COVID-19. XORTX's lead product candidate, XRx-008, is a late clinical-stage program aimed at treating ADPKD, a genetic disorder characterized by the growth of numerous cysts in the kidneys. XRx-101 is being developed as a uric acid-lowering agent to mitigate AKI and associated health consequences in patients infected with COVID-19. XRx-221 represents another key pipeline asset, targeting diabetic nephropathy through xanthine oxidase inhibition. The company collaborates with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in COVID-19 patients, underscoring its commitment to addressing critical healthcare challenges. With a focus on innovative therapies and strategic partnerships, XORTX aims to improve outcomes for patients suffering from kidney diseases and related complications.
What Products and Services Does XRTX Offer?
- Develop therapies for progressive kidney diseases.
- Focus on treating autosomal dominant polycystic kidney disease (ADPKD).
- Develop treatments for acute kidney injury (AKI) associated with COVID-19.
- Create therapies for diabetic nephropathy.
- Research uric acid-lowering agents.
- Develop xanthine oxidase inhibitors.
How Does XRTX Make Money?
- Develop and commercialize pharmaceutical products.
- Out-license or partner for commercialization.
- Generate revenue through product sales.
- Seek research and development funding.
What Industry Does XRTX Operate In?
The biotechnology industry is characterized by high risk and high reward, with companies like XORTX Therapeutics focusing on developing innovative therapies for unmet medical needs. The kidney disease market is substantial and growing, driven by factors such as the increasing prevalence of diabetes and hypertension. Competition includes companies developing treatments for specific kidney disorders, such as ADPKD and diabetic nephropathy. XORTX's focus on multiple kidney-related conditions positions it to capitalize on the growing demand for effective therapies in this space.
Who Are XRTX's Key Customers?
- Patients with kidney diseases.
- Hospitals and clinics.
- Healthcare providers.
- Pharmaceutical distributors.
Company Profile
XORTX Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Calgary, CA. The company is led by CEO Allen Warren Davidoff. XRTX has traded publicly since 2021.
Key Financial Metrics
Return on assets is -59.7%, showing how much profit it generates from its asset base. A current ratio of 3.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -110.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
XORTX Therapeutics Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.98 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project XORTX Therapeutics Inc. revenue of about $3.3M for fiscal 2026, with EPS near $-1.75.
XRTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- XORTX's focus on kidney disease is hitting a major unmet need, and the market is starting to notice.
- Recent insider buying suggests those in the know see long-term value, a positive signal for the stock.
- Community chatter highlights growing excitement around potential trial results, creating positive momentum.
- The company's strategic partnerships could open doors to wider market access and future revenue streams.
Bear Case
- The biotech sector is notoriously volatile; XORTX is not immune to market downturns or shifting investor sentiment.
- Negative community sentiment has increased recently, with some expressing concerns about trial delays.
- Competition in the kidney disease space is fierce; XORTX faces established players with deeper pockets.
- Small-cap biotechs are heavily reliant on successful trial outcomes; any setback could significantly impact the stock.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
XRTX Latest News
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · Jun 30, 2026
XRTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for XRTX.
Price Targets
Wall Street price target analysis for XRTX.
XRTX MoonshotScore
What does this score mean?
The MoonshotScore rates XRTX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Allen Warren Davidoff
CEO
Allen Warren Davidoff serves as the CEO of XORTX Therapeutics Inc. His background includes experience in managing and leading small teams, as evidenced by his role overseeing the company's two employees. Information regarding his specific educational background and previous roles is not available in the provided data. However, his current position indicates a leadership role in guiding the strategic direction and operations of the company.
Track Record: Due to the limited information available, it is difficult to assess Allen Warren Davidoff's specific track record at XORTX Therapeutics Inc. However, his leadership is presumably focused on advancing the company's clinical programs, securing funding, and building strategic partnerships. The success of XRx-008 and other pipeline candidates will be key indicators of his leadership effectiveness.
XRTX Healthcare Stock FAQ
What does XORTX Therapeutics Inc. do?
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for progressive kidney diseases, diabetes, and related complications. Their lead product candidate, XRx-008, is in late-stage clinical development for autosomal dominant polycystic kidney disease (ADPKD).
What are the main risks for XRTX?
XORTX Therapeutics Inc. faces several key risks, including the potential for clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies. The company's dependence on securing additional funding also poses a risk, as does the potential for patent expirations and intellectual property challenges. Given its small size and limited resources, XORTX is particularly vulnerable to these risks. Investors should carefully consider these factors before investing in XRTX.
What are the key factors to evaluate for XRTX?
Evaluate XRTX on fundamentals, analyst consensus, and risk factors. XORTX Therapeutics presents a notable research candidate due to its focus on addressing significant unmet needs in kidney disease and related metabolic disorders. Not financial advice.
How frequently does XRTX data refresh on this page?
XRTX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven XRTX's recent stock price performance?
XORTX Therapeutics Inc. (XRTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on unmet needs in kidney disease. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XRTX overvalued or undervalued right now?
XORTX Therapeutics Inc. (XRTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research XRTX before investing?
Before investing in XORTX Therapeutics Inc. (XRTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding XRTX to a portfolio?
Key strength of XORTX Therapeutics Inc. (XRTX): Focus on unmet needs in kidney disease. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO track record.
- AI analysis pending.